Cited 6 times in
A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김진석 | - |
dc.date.accessioned | 2018-11-23T11:33:34Z | - |
dc.date.available | 2018-11-23T11:33:34Z | - |
dc.date.issued | 2017 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/165810 | - |
dc.description.abstract | Bortezomib-melphalan-prednisone (VMP) showed superior efficacy versus MP as first-line treatment for transplantation-ineligible multiple myeloma (MM). This study investigated the efficacy of VMP for Korean patients with MM.Overall, 177 MM patients received 9 cycles of VMP in this prospective, multicenter, observational study. The primary endpoint was 2-year progression-free survival (PFS).Thirty-nine (22%) patients were aged ≥ 75 years and 83 (47.4%) patients had International Staging System stage III. A median of 5 cycles were delivered. Overall response rate (ORR) was 72.9%, and complete response (CR) rate was 20.3%. With a median follow-up of 11.9 months, median PFS was 17 months. The 2-year PFS and overall survival (OS) rates were 29.2% and 80.0%, respectively. Median OS was not reached. PFS was significantly different depending on performance status (Eastern Cooperative Oncology Group < 2 vs. ≥ 2; p = 0.0002), β2-microglobulin level (< 5.5 vs. ≥ 5.5 mg/L; p = 0.0481), and cumulative dose of bortezomib (< 35.1 vs. ≥ 35.1 mg/m2; p < 0001). The common adverse events (AEs) were in line with the well-known toxicity profiles associated with VMP.In conclusion, VMP is a feasible and effective front-line treatment for transplant-ineligible older patients with MM in Korea. Continuing therapy with prompt adjustment of treatment according to AEs may be important to improve outcomes of elderly patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Impact Journals | - |
dc.relation.isPartOf | ONCOTARGET | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Asian Continental Ancestry Group | - |
dc.subject.MESH | Bortezomib/administration & dosage | - |
dc.subject.MESH | Bortezomib/adverse effects | - |
dc.subject.MESH | Diarrhea/chemically induced | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Melphalan/administration & dosage | - |
dc.subject.MESH | Melphalan/adverse effects | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Multiple Myeloma/drug therapy* | - |
dc.subject.MESH | Multiple Myeloma/ethnology | - |
dc.subject.MESH | Multiple Myeloma/pathology | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Neutropenia/chemically induced | - |
dc.subject.MESH | Prednisone/administration & dosage | - |
dc.subject.MESH | Prednisone/adverse effects | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Min Kyoung Kim | - |
dc.contributor.googleauthor | Kihyun Kim | - |
dc.contributor.googleauthor | Chang-Ki Min | - |
dc.contributor.googleauthor | Jae-Yong Kwak | - |
dc.contributor.googleauthor | Sang-Byung Bae | - |
dc.contributor.googleauthor | Sung-Soo Yoon | - |
dc.contributor.googleauthor | Je-Jung Lee | - |
dc.contributor.googleauthor | Ki Hwan Kim | - |
dc.contributor.googleauthor | Seung-Hyun Nam | - |
dc.contributor.googleauthor | Yeung-Chul Mun | - |
dc.contributor.googleauthor | Hyo Jung Kim | - |
dc.contributor.googleauthor | Sung Hwa Bae | - |
dc.contributor.googleauthor | Ho-Jin Shin | - |
dc.contributor.googleauthor | Jung-Hee Lee | - |
dc.contributor.googleauthor | Joon Seong Park | - |
dc.contributor.googleauthor | Seong Hyun Jeong | - |
dc.contributor.googleauthor | Mark Hong Lee | - |
dc.contributor.googleauthor | Yang-Soo Kim | - |
dc.contributor.googleauthor | Ho Sup Lee | - |
dc.contributor.googleauthor | Keon Woo Park | - |
dc.contributor.googleauthor | Won-Sik Lee | - |
dc.contributor.googleauthor | Sang Min Lee | - |
dc.contributor.googleauthor | Jeong-Ok Lee | - |
dc.contributor.googleauthor | Myung Soo Hyun | - |
dc.contributor.googleauthor | Deog Yeon Jo | - |
dc.contributor.googleauthor | Sung-Nam Lim | - |
dc.contributor.googleauthor | Jae Hoon Lee | - |
dc.contributor.googleauthor | Do-Yeun Cho | - |
dc.contributor.googleauthor | Young Rok Do | - |
dc.contributor.googleauthor | Jeong-A Kim | - |
dc.contributor.googleauthor | Seong Kyu Park | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.contributor.googleauthor | Soo-Jeong Kim | - |
dc.contributor.googleauthor | Hawk Kim | - |
dc.contributor.googleauthor | Hyeon Gyu Yi | - |
dc.contributor.googleauthor | Joon Ho Moon | - |
dc.contributor.googleauthor | Chul Won Choi | - |
dc.contributor.googleauthor | Sung-Hyun Kim | - |
dc.contributor.googleauthor | Young-Don Joo | - |
dc.contributor.googleauthor | Hoon-Gu Kim | - |
dc.contributor.googleauthor | Byung Soo Kim | - |
dc.contributor.googleauthor | Moo-Rim Park | - |
dc.contributor.googleauthor | Moo-Kon Song and Su-Youn Kim | - |
dc.identifier.doi | 10.18632/oncotarget.16790 | - |
dc.contributor.localId | A01017 | - |
dc.relation.journalcode | J02421 | - |
dc.identifier.eissn | 1949-2553 | - |
dc.identifier.pmid | 28402945 | - |
dc.subject.keyword | aged | - |
dc.subject.keyword | bortezomib | - |
dc.subject.keyword | combination | - |
dc.subject.keyword | drug therapy | - |
dc.subject.keyword | multiple myeloma | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | 김진석 | - |
dc.citation.volume | 8 | - |
dc.citation.number | 23 | - |
dc.citation.startPage | 37605 | - |
dc.citation.endPage | 37618 | - |
dc.identifier.bibliographicCitation | ONCOTARGET , Vol.8(23) : 37605-37618, 2017 | - |
dc.identifier.rimsid | 60551 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.